ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 227 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,147 | -13.0% | 199 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $4,766 | +27.3% | 199 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,745 | +18.2% | 199 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $3,168 | -36.6% | 199 | -29.2% | 0.00% | -33.3% |
| Q3 2022 | $5,000 | +25.0% | 281 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $4,000 | -42.9% | 281 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $7,000 | +40.0% | 281 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $5,000 | -28.6% | 281 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $7,000 | 0.0% | 281 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $7,000 | -53.3% | 281 | 0.0% | 0.00% | -60.0% |
| Q4 2020 | $15,000 | +15.4% | 281 | 0.0% | 0.01% | -23.1% |
| Q2 2020 | $13,000 | -27.8% | 281 | -42.9% | 0.01% | +8.3% |
| Q3 2019 | $18,000 | +28.6% | 492 | -5.7% | 0.01% | +33.3% |
| Q2 2019 | $14,000 | 0.0% | 522 | 0.0% | 0.01% | -18.2% |
| Q1 2019 | $14,000 | +27.3% | 522 | -5.1% | 0.01% | +120.0% |
| Q3 2018 | $11,000 | – | 550 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |